McKinley Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

McKinley Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-109,512	Closed	-$13.5M	–	190
2020 Q2	$13.5M	Buy	+109,512	New	+$10.9M	0.92%	38
2014 Q2	–	Sell	-175,570	Closed	-$12M	–	349
2014 Q1	$12M	Sell	175,570 -21,794	-11%	-$1.61M	0.5%	54
2013 Q4	$13.9M	Buy	197,364 +2,995	+2%	+$203K	0.54%	48
2013 Q3	$14M	Sell	194,369 -2,910	-1%	-$193K	0.61%	47
2013 Q2	$11M	Buy	+197,279	New	+$12.3M	0.55%	51

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

McKinley Capital Management's BMRN Position: Q3 2020 in Review

McKinley Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 109,512 shares — an estimated $13.5M sold.

McKinley Capital Management first reported a position in BMRN in Q2 2013 and held it in 5 quarters. The position peaked at $14M in Q3 2013. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

McKinley Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
McKinley Capital Management sold 109,512 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $13.5M.
McKinley Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 5 quarters.
McKinley Capital Management's BioMarin Pharmaceuticals position peaked at $14M in Q3 2013.
496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on McKinley Capital Management's 13F filing for Q3 2020, filed 2 Nov 2020.